Haisco Pharmaceutical Group Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS30
PHASE 3 / 2-311
RECRUITING12
READOUTS ≤12 MONTHS14
READOUT SLIPPED >6 MO0%
Delay Index: of 8 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Haisco Pharmaceutical Group Co., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| HSK39004 Dry Powder Inhaler -0.75mg BID NCT07140328 |
P2 | Recruiting | Chronic Obstructive Lung Disease (COLD) | 50 | 2025-07-10 |
| HSK39004 inhalation suspension NCT07331402 |
P2 | Active, not recruiting | COPD Patients | 12 | 2025-12-30 |
| HSK31858 NCT06820749 |
P2 | Enrolling by invitation | Asthma Bronchiale; Bronchiectasis | 309 | 2026-04-23 |
| HSK44459 NCT06902428 |
P2 | Not yet recruiting | Behcet's Disease | 120 | 2026-06-05 |
| HSK39004 Dry Powder Inhaler-0.75mg NCT07108699 |
P2 | Active, not recruiting | Chronic Obstructive Pulmonary Disease (COPD) | 180 | 2026-08-30 |
| IPF NCT07019090 |
P2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 120 | 2026-10-31 |
| HSK55718 dose level 1 NCT07551739 |
P2 | Not yet recruiting | Pain After Surgery | 200 | 2026-11 |
| HSK44459 dose level 1 NCT07150988 |
P2 | Not yet recruiting | Psoriasis | 150 | 2026-11-06 |
| HSK55718 dose level1 NCT07533786 |
P2 | Recruiting | Pain After Surgery | 200 | 2026-11-22 |
| HSK31858, tablet NCT06660992 |
P3 | Recruiting | Non-cystic Fibrosis Bronchiectasis | 669 | 2026-11-28 |
| HSK39297 200mgQD NCT07616700 |
P2 | Recruiting | IgA Nephropathy (IgAN) | 73 | 2026-12-05 |
| HSK47388 NCT07158268 |
P2 | Not yet recruiting | Plaque Psoriasis | 220 | 2026-12-20 |
| HSK44459 Cream NCT07623486 |
P1/2 | Active, not recruiting | Psoriasis | 180 | 2027-03 |
| HSK39297 tablets NCT06745622 |
P2 | Recruiting | Paroxysmal Nocturnal Hemoglobinuria | 47 | 2027-06 |
| HSK39004 Inhalation Suspension NCT07658339 |
P3 | Not yet recruiting | COPD (Chronic Obstructive Pulmonary Disease) | 387 | 2027-06-11 |
| HSK39004 Dry Powder Inhaler -0.75mg BID NCT07425210 |
P2 | Not yet recruiting | Chronic Obstructive Lung Disease (COLD) | 300 | 2027-07 |
| HSK44459 tablets NCT07070739 |
P2 | Not yet recruiting | Bechet's Disease | 120 | 2027-07 |
| HSK16149 20mg-40mg BID NCT06422117 |
P3 | Not yet recruiting | Central Neuropathic Pain | 408 | 2027-07-30 |
| HSK39004 Dry Powder Inhaler Simulant NCT07583849 |
P3 | Recruiting | COPD (Chronic Obstructive Pulmonary Disease) | 376 | 2027-09-30 |
| HSK47388 NCT07335055 |
P2 | Recruiting | Ulcerative Colitis (UC) | 150 | 2027-10-15 |
| HSK39297 200mgQD NCT07363460 |
P2 | Recruiting | Lupus Nephritis (LN) | 105 | 2027-11-05 |
| HSK39297 NCT07390123 |
P3 | Recruiting | IgA Nephropathy (IgAN) | 370 | 2027-12 |
| HSK39004 Inhalation Suspension NCT07634367 |
P3 | Not yet recruiting | COPD (Chronic Obstructive Pulmonary Disease) | 300 | 2027-12-24 |
| HSK44459 NCT07519070 |
P3 | Not yet recruiting | IPF | 420 | 2028-04-05 |
| IPF NCT07728721 |
P2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 175 | 2028-04-10 |
| HSK3486 NCT07510945 |
P3 | Not yet recruiting | General Anesthetic | 400 | 2028-05 |
| PPF NCT07503587 |
P3 | Not yet recruiting | Progressive Pulmonary Fibrosis | 378 | 2028-12-30 |
| HSK31858, tablet NCT07616375 |
P3 | Recruiting | Non-cystic Fibrosis Bronchiectasis | 669 | 2029-01-10 |
| HSK31679 NCT07581951 |
P3 | Recruiting | MASH - Metabolic Dysfunction-Associated Steatohepatitis; NASH (Non-Alcoholic Steatohepatitis) | 886 | 2029-06-30 |
| HSK42360-Na Tablets NCT07790510 |
P1/2 | Recruiting | Metastatic Colorectal Cancer (CRC) | 180 | 2029-09-30 |